Table 3

Risk of GORD among hormone replacement users: multiple regression
Oestrogen-only users No. of GORD cases OR (95% CI) P Tibolone users No. of GORD cases OR (95% CI) P Combined HRT users No. of GORD cases OR (95% CI) P Progestogen users No. of GORD cases OR (95% CI) P
GORD
Hormone 144 21 137 56
Non-hormone 572 572 572 572
OR (95% CI) p 1.49 (1.18–1.89) 0.001 0.79 (0.45–1.4) 0.419 1.09 (0.87–1.37) 0.445 1.29 (0.90–1.84) 0.170
NSAIDs <30d
Hormone 23 3 22 12
Non-hormone 99 99 99 99
OR (95% CI) p 1.52 (1.09–2.12) 0.014 1.08 (0.48–2.48) 0.848 1.25 (0.92–1.71) 0.150 1.09 (0.68–1.74) 0.718
NSAIDs ≥30d
Hormone 75 14 62 21
Non-hormone 233 233 233 233
OR (95% CI) p 2.06 (1.59–2.66) < 0.001 3.42 (1.22–9.64) 0.020 1.97 (1.56–2.50) < 0.000 1.14 (0.77–1.68) 0.520
Calcium <30d
Hormone 1 0 0 0
Non-hormone 10 10 10 10
OR (95% CI) p 0.56 (0.13–2.41) 0.439 1.58 (0.31–8.02) 0.582 0.49 (0.11–2.06) 0.325 4.14 (1.40–12.27) 0.010
Calcium ≥30d
Hormone 11 2 11 0
Non-hormone 37 37 37 37
OR (95% CI) p 2.15 (1.26–3.66) 0.005 1.88 (0.53–6.72) 0.330 1.99 (1.18–3.36) 0.010 1.64 (0.523–5.07) 0.393
Bisphosphonate <30d
Hormone 0 0 1 0
Non-hormone 3 3 3 3
OR (95% CI) p 0.56 (0.06–4.80) 0.592 - (−) 0.999 1.11 (0.29–4.26) 0.886 - (−) 0.999
Bisphosphonate ≥30d
Hormone 6 0 4 0
Non-hormone 12 12 12 12
OR (95% CI) p 0.93 (0.43–2.04) 0.865 0.84 (0.15–4.75) 0.845 0.69 (0.27–1.79) 0.445 0.75 (0.13–4.27) 0.744

This table shows the number of prospective GORD positive events for hormone replacement use and non-use.

Close et al.

Close et al. BMC Gastroenterology 2012 12:56   doi:10.1186/1471-230X-12-56

Open Data